#China #Beijing #Haisco #Sentivera #Population Health Partners

Haisco's Exclusive Licensing Agreement with Sentivera

In a significant move for global healthcare solutions, Haisco Pharmaceutical Group Co., Ltd. has officially entered into an exclusive licensing agreement with Sentivera, a new venture established by Population Health Partners (PHP) and ARCH Venture Partners. Announced on August 25, 2026, the agreement grants Sentivera full rights to develop, manufacture, and commercialize an innovative pre-clinical drug globally, with exceptions for Greater China.

Deal Highlights

The collaboration is valued at over USD 1.5 billion, featuring an upfront payment and equity considerations totaling approximately USD 75.89 million. The agreement further includes development and regulatory milestone payments that could amount to USD 1.46 billion. Additionally, Sentivera will benefit from tiered royalties ranging from mid-single digits to low double digits on net sales post-launch.

Haisco’s key immunology asset, focusing on type 2 inflammatory diseases, has recently received IND approval in China, highlighting its potential as a strong candidate for international markets. Preclinical studies have indicated that this asset possesses notable anti-inflammatory properties and a positive safety profile, underscoring its viability for treating a range of inflammatory conditions.

Significance of the Collaboration

This strategic partnership symbolizes a critical step in bringing innovative Chinese drug solutions to the international stage. By collaborating with leading life sciences investors such as PHP and ARCH, Haisco demonstrates confidence in the project's market potential and enhances its ability to address unmet health needs worldwide. This initiative is aligned with global strategies to improve health outcomes and reduce the burden of inflammatory diseases.

Haisco's Vision

Haisco is dedicated to fostering innovation and global outreach in healthcare. The company has outlined its commitment to focusing on unmet clinical needs, emphasizing independent research and development (R&D) while establishing international collaborations. By leveraging its extensive pipeline, Haisco aims to introduce original medicines developed in China to patients across the globe.

Haisco's R&D capabilities are anchored in a diverse portfolio that encompasses small-molecule innovative drugs, biologics, and high-end generics. The company currently advances over 70 R&D programs in areas such as oncology, respiratory issues, and metabolic disorders, with more than 10 programs being in pivotal clinical stages. Haisco's consistent investment in R&D—averaging over 15% of its revenue for the past three years—demonstrates its resolve to sustain growth and innovation.

Establishing a New Paradigm

Unlike conventional licensing models, this partnership adopts a Newco structure that fosters deeper strategic alignment between Haisco and Sentivera. By sharing growth and resources, both entities aim to enhance their global market influence. This deal also sets a precedent for how Chinese pharmaceutical companies like Haisco can engage with international markets, establishing a framework for future collaborations and innovations.

As Haisco continues to navigate its expansion strategy, the future looks bright for the company, with high expectations for the performance of its new immunology asset in global healthcare. With this venture, Haisco reinforces its role as a pioneer in the innovative drug landscape, paving the way for greater accessibility to robust medical solutions worldwide.

In conclusion, the collaboration between Haisco and Sentivera not only showcases the potential of emerging biopharma partnerships but also emphasizes the transformative impact of international cooperation on healthcare innovation. As Haisco progresses in its journey of expansion, the pharmaceutical industry watches closely, eager to see how this partnership unfolds and the benefits it may bring to patients around the globe.